Motac Neuroscience (United Kingdom)

Recent papers from Motac Neuroscience (United Kingdom)

1. LAMP2A gene therapy mitigates Parkinson’s disease–related pathology in nonhuman primatesScience Advances · 2026
2. Age-Related Maturation of Antiphasic Arabic Digits-in-Noise Thresholds in ChildrenJournal of Speech Language and Hearing Research · 2026
3. A science museum 'to rival South Kensington': historicizing the industrial city and galvanizing 'modern' science in post-war Manchester.2026
4. High-accuracy electrode implantation in deep brain structures using multi-camera neuronavigation in non-human primatesJournal of Neural Engineering · 2025
5. Additive effect of distant Lewy bodies and tau seeds injections on nigral degeneration in macaquesnpj Parkinson s Disease · 2025
6. In vivo bioluminescence imaging of the intracerebral fibroin-controlled AAV-α-synuclein diffusion for monitoring the central nervous system and peripheral expressionScientific Reports · 2024
7. Perturbation of serine enantiomers homeostasis in the striatum of MPTP-lesioned monkeys and mice reflects the extent of dopaminergic midbrain degenerationNeurobiology of Disease · 2023
8. Rationale and Development of Tavapadon, a D1/D5-Selective PartialDopamine Agonist for the Treatment of Parkinson’s DiseaseCNS & Neurological Disorders - Drug Targets · 2023
9. Trajectories of self-reported hearing and their associations with cognition: evidence from the United Kingdom and United States of AmericaAge and Ageing · 2023
10. Monitoring α-synuclein aggregationNeurobiology of Disease · 2022
11. A Novel C-Type Lectin Receptor-Targeted α-Synuclein-Based Parkinson Vaccine Induces Potent Immune Responses and Therapeutic Efficacy in MiceVaccines · 2022
12. Basal ganglia neuropeptides show abnormal processing associated with L-DOPA-induced dyskinesianpj Parkinson s Disease · 2022
13. Dopaminergic co-transmission with sonic hedgehog inhibits abnormal involuntary movements in models of Parkinson’s disease and L-Dopa induced dyskinesiaCommunications Biology · 2021
14. Adenosine A2AR/A1R Antagonists Enabling Additional H3R Antagonism for the Treatment of Parkinson’s DiseaseJournal of Medicinal Chemistry · 2021
15. Involvement of Autophagy in Levodopa‐Induced DyskinesiaMovement Disorders · 2021
16. Mass spectrometry imaging identifies abnormally elevated brain l -DOPA levels and extrastriatal monoaminergic dysregulation in l -DOPA–induced dyskinesiaScience Advances · 2021
17. L‐DOPA regulates α‐synuclein accumulation in experimental parkinsonismNeuropathology and Applied Neurobiology · 2020
18. Gastrointestinal and metabolic function in the MPTP-treated macaque model of Parkinson's diseaseHeliyon · 2020
19. µ Opioid Receptor Agonism for L-DOPA-Induced Dyskinesia in Parkinson's DiseaseJournal of Neuroscience · 2020
20. RasGRP1 is a causal factor in the development of l -DOPA–induced dyskinesia in Parkinson’s diseaseScience Advances · 2020